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Leptin acts on the central nervous systemto cause a reduction in food intake and
body weight1,2. The melanocortin system in
the brain is also implicated in energy homeo-
stasis, with agonists of the melanocortin-4
(MC4) receptor reducing food intake3 and
targeted mutation of the MC4 receptor caus-
ing obesity4. We now show that MC4 recep-
tor signalling is an important mediator of
leptin’s effects on food intake and body
weight, demonstrating a link between the
two systems.
Leptin receptors are on proopiomelano-
cortin (POMC) neurons in the arcuate
nucleus5 that synthesize melanocortins,
therefore it seemed likely that leptin-induced
reductions in food intake might be mediated
by the melanocortin system. To test this
hypothesis, we determined whether pharma-
cological blockade of MC4 receptors attenu-
ates the ability of leptin to reduce food intake
or body weight. Because leptin also activates
the hypothalamic paraventricular nucleus
(PVN), as measured by c-Fos expression, we
also wished to determine whether this
response involves melanocortin receptors.
We injected male Long–Evans rats with
the non-selective MC4 receptor antagonist
SHU9119 into the third cerebral ventricle
(i3vt). There was a significant increase in
food intake 4 and 24 h after administration
of 1 nmol SHU9119, whereas 0.5 nmol
altered neither food intake nor body weight
at any time point. We therefore pretreated
rats with 0.5 nmol of SHU9119 or vehicle
i3vt before an i3vt injection of 3.5 mg of
recombinant leptin or its vehicle (see ref. 1
for details). Consistent with previous find-
ings1, leptin alone significantly reduced food
intake after 4 h (154%) and after 24 h
(146%, P*0.05; Fig. 1a), and reduced body
weight after 24 h (118.6 g, P*0.05). How-
ever, when these same animals were pretreat-
ed with SHU9119, leptin did not affect food
intake or body weight. 
To assess the specificity of SHU9119 to
reverse anorexia induced by leptin, we
administered glucagon-like-peptide-1 (7–36)
amide (GLP-1), a potent inducer of anorexia
when given intracerebroventricularly6–9. The
dose of GLP-1 (10 mg i3vt) that we selected
reduces short-term food intake to an extent
comparable to 3.5 mg leptin7 (163% after 4
h) and this effect was not altered by pretreat-
ment with 0.5 nmol SHU9119 (Fig. 1b).
We assessed cFos-like-immunoreactivity
in the PVN after leptin treatment with or
without SHU9119 pretreatment (see ref. 10
for methods). Consistent with our previous
findings10, leptin increased c-Fos-like
immunoreactivity in the PVN by 254%,
and this was completely blocked by
SHU9119 (Fig. 1c).
Our findings provide direct evidence that
MC4 receptor signalling is important in
mediating leptin’s effect on food intake and
body weight. We suggest that obesity stem-
ming from disrupted MC4 receptor sig-
nalling (for example, MC4-R knockout and
agouti mice) results from the loss of an
important downstream target in the leptin
signalling cascade. The possibility that the
melanocortin system is one mediator of lep-
tin’s action in the central nervous system is
particularly intriguing in light of the recent
finding that human obesity and hyperleptin-
aemia are strongly linked to a region of chro-
mosome 2 near the POMC gene locus11. The
hypothesis that polymorphisms of the
POMC gene are associated with leptin resis-
tance and obesity is consistent with our find-
ings implicating melanocortins in the leptin
signalling pathway, and may have important
implications for the pathogenesis and treat-
ment of human obesity.
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Figure 1 Effect of treatment with a melanocortin
receptor antagonist on feeding and the leptin
response (means±s.e.m.). V, vehicle; A, antagonist; L,
leptin. Data were analysed by a one-way ANOVA fol-
lowed by post-hoc Neuman–Keul’s tests. * Significant
difference from the vehicle-only group at P*0.05; ** at
P*0.01. a, Effect of pretreatment with i3vt SHU9119 (0.5
nmol) on the anorexic response to i3vt leptin (3.5 mg)
on 4-h food intake. Leptin treatments, n412; vehicle
treatments, n46. b, The effect of pretreatment with
i3vt SHU9119 (0.5 nmol) on the anorexic response to
i3vt GLP-1 (10 mg) on 4-h food intake. GLP-1, n45; vehi-
cle group, n44. c, Effect of pretreatment with i3vt
SHU9119 (0.5 nmol) on c-Fos activation in the PVN of
the hypothalamus produced by i3vt leptin (3.5 mg)




Melanocortin receptors in leptin effects
The introduction of a potent transcriptional
activator into eukaryotic cells can paradoxi-
cally suppress the transcription of a co-intro-
duced target gene1–3. This so-called
‘squelching’ is thought to result from titra-
tion of one or more general transcription
factors (GTFs)4, indicating that GTFs might
be in limited supply within the cell5,6. We
now find that in mammalian cells, squelch-
ing is limited to episomal target genes,
whereas genes integrated into cellular chro-
matin are immune.
During the process of designing more
potent transcriptional activation domains
for use in gene therapy, we constructed chi-
maeric transcription factors composed of the
yeast GAL4 DNA-binding domain and acti-
vation domains derived from the herpes sim-
plex virus protein VP167 and the NF-kB p65
protein8. We tested the proteins on a target
gene composed of a secreted alkaline phos-
phatase (SEAP) reporter under the control of
a minimal human interleukin-2 (IL-2) gene
promoter flanked by five GAL4 binding sites. 
When we transiently introduced the
